← Oncology Approval Tracker

FDA DECISION ·

Tazverik

tazemetostat · Epizyme

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Jun 22, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma with an EZH2 mutation on an FDA-approved test after at least two systemic therapies, or adults with relapsed or refractory disease with no satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

Expanded EZH2 inhibition to follicular lymphoma under two historical eligibility routes.

What research teams should watch

Track the biomarker and prior-treatment criteria independently from the no-alternative route.

PRIMARY RECORDS

Sources